EIF4E

eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences

Retrieved on: 
Monday, October 31, 2022
Escape Room, RNA transfection, EIF4E, Therapy, Survival, Stri, MNK, Pfizer, Pembrolizumab, KRAS, Cancer, 4F, GLOBE, STRI, COVID-19, University of California, San Francisco, ER, University, NASDAQ, Investor, Protein, Patient, San Francisco, SAN, DARPA, NSCLC, EIF4A, Pharmaceutical industry, KICKSTART

A replay of the webcasts will be available for 30 days following the event.

Key Points: 
  • A replay of the webcasts will be available for 30 days following the event.
  • eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of oncology drugs referred to as STRIs.
  • eFFECTORs STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase interacting kinase (MNK).
  • eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E.

eFFECTOR Therapeutics Completes Enrollment in Second of Three Cohorts of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19

Retrieved on: 
Wednesday, October 26, 2022
Genome, Stri Parva, Survival, University, Virus, Clinical trial, Security (finance), University of California, San Francisco, U.S. Securities and Exchange Commission, STRI, NASDAQ, Private Securities Litigation Reform Act, Safety, Cancer, Prevalence, Vaccine, CDK, EIF4E, 4F, Receptor tyrosine kinase, Pembrolizumab, COVID-19, KRAS, RNA, Patient, QBI, Effector, Protein, Disease, Orthornavirae, Research, NSCLC, GLOBE, EIF4A, University of California, ER, Therapy, UC, RNA transfection, SAN, UC San Diego Health, Membrane protein, UCSF, Biology, Escape Room, Severe acute respiratory syndrome coronavirus 2, MNK, DARPA, Pfizer, Solution, Pharmaceutical industry, KICKSTART, Nature, Pharmacy

eFFECTOR anticipates opening enrollment in the third cohort by the end of 2022, and expects to report topline data for all three cohorts in the first half of 2023.

Key Points: 
  • eFFECTOR anticipates opening enrollment in the third cohort by the end of 2022, and expects to report topline data for all three cohorts in the first half of 2023.
  • Zotatifin is an investigational host-directed antiviral, meaning that it acts on a human protein that the SARS-CoV-2 virus hijacks to synthesize new viruses.
  • As such, zotatifin may have a higher barrier to viral mutational escape than therapies that target components of the virus itself.
  • eFFECTOR cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements.

AUM Biosciences, a Global Biotechnology Company Developing Precision Oncology Therapeutics, Announces Plans to Become a Public Company via Merger with Mountain Crest Acquisition Corp. V

Retrieved on: 
Thursday, October 20, 2022
MSD, CFO, Merck, Therapy, Registration statement, IND, Merck & Co., Investigational New Drug, Securities Act of 1933, Board of directors, Mutation, CEO, Director, Failure, LLP, Nasdaq, Pedigree, MNK, Trk receptor, AUMB, Regulation of tobacco by the U.S. Food and Drug Administration, Agreement, AUM, Private Securities Litigation Reform Act, NEW, EIF4E, Industry, SPAC, GLOBE, Trichuris suis, Ownership, Leadership, MTOR, Orphan, Risk, Growth, Roche, Register, Research, Security (finance), DLA Piper, TRK, Board, U.S. Securities and Exchange Commission, Prospectus, Name, Sale, Cayman Islands, SEC, Patient, Partnership, Food, Acquisition, F-4, Form, File, Proxy, COVID-19, Health, Bank, Fine chemical, Pharmaceutical industry, Financial adviser, Risk management, Holding company, Greater China

The transaction is expected to provide approximately $69 million of cash held in Mountain Crests trust account, assuming no redemptions.

Key Points: 
  • The transaction is expected to provide approximately $69 million of cash held in Mountain Crests trust account, assuming no redemptions.
  • This merger allows AUM to further continue our focus on developing our scientifically differentiated portfolio.
  • AUM is a global clinical-stage oncology company focused on advancing a clinical stage pipeline of precision oncology therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance.
  • Mountain Crest and AUM caution readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made.

PIC Therapeutics Completes $35 Million Series A Financing to Develop Treatments for Drug-Resistant Breast Cancer

Retrieved on: 
Wednesday, October 19, 2022
Oncology, Professional Services, Health, Insurance, Managed Care, Pharmaceutical, Biotechnology, McGill University, Pharmacology, PIC, RNA transfection, Therapy, Plague, Partner, Complex, Patient, Biotechnology, Drug resistance, Cancer, SAP BusinessObjects Lumira, Goal, EIF4E, Harvard University, Apoptosis, Allosteric regulation, Solution, Pharmaceutical industry

PIC Therapeutics, Inc., a biopharmaceutical company dedicated to developing life-changing medicines for patients with cancer, today announced the closing of a $35 million Series A financing led by OrbiMed.

Key Points: 
  • PIC Therapeutics, Inc., a biopharmaceutical company dedicated to developing life-changing medicines for patients with cancer, today announced the closing of a $35 million Series A financing led by OrbiMed.
  • PIC Therapeutics is targeting a fundamental mechanism at the convergence of many oncogenic signaling pathways that results in apoptotic cancer cell death while sparing normal cells.
  • PIC Therapeutics targets a master switch of cancer signaling pathways, selectively impacting oncogene protein production by altering the Pre-Initiation Complex (PIC) that drives their mRNA translation.
  • PIC Therapeutics' selective approach modulates cancer cell proteomes, impacting multiple dysregulated oncogenic drivers leading to a powerful new generation of cancer-treating therapeutics.

eFFECTOR Therapeutics Appoints Mayank Gandhi, M.D., as Chief Business Officer

Retrieved on: 
Monday, September 26, 2022
University, EIF4E, Therapy, Stri Parva, COVID-19, University of California, San Francisco, Effector, RNA transfection, EIF4A, NSCLC, Acquisition, DARPA, Private Securities Litigation Reform Act, Partnership, STRI, VC, ER, U.S. Securities and Exchange Commission, Cancer, Survival, Patient, Clinical trial, IPO, Atezolizumab, Protein, San Francisco, NASDAQ, Negotiation, SAN, KRAS, Akira Toriyama's Manga Theater, MNK, Research, GLOBE, Security (finance), Case Western Reserve University, Genentech, Pembrolizumab, Escape Room, Citigroup, 4F, Pfizer, Pharmaceutical industry, KICKSTART

SAN DIEGO and REDWOOD CITY, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced it has appointed Mayank J. Gandhi, M.D., as chief business officer.

Key Points: 
  • SAN DIEGO and REDWOOD CITY, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced it has appointed Mayank J. Gandhi, M.D., as chief business officer.
  • Mayank is an accomplished leader with extensive experience in the biopharmaceutical industry including corporate development, partnering, product development and commercialization, said Steve Worland, Ph.D., president and chief executive officer of eFFECTOR.
  • Mayank will be instrumental in maximizing the value of tomivosertib and zotatifin as both compounds advance in clinical development.
  • eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of oncology drugs referred to as STRIs.

eFFECTOR Therapeutics to Present at Cantor Oncology, Hematology, HemeOnc Conference

Retrieved on: 
Wednesday, September 21, 2022
EIF4E, Stri, COVID-19, University of California, San Francisco, Effector, RNA transfection, EIF4A, NSCLC, DARPA, 4F, Survival, STRI, Patient, ER, Cancer, Protein, San Francisco, KRAS, Escape Room, Pembrolizumab, University, MNK, Pfizer, Pharmaceutical industry, Vaccine, KICKSTART

eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of oncology drugs referred to as STRIs.

Key Points: 
  • eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of oncology drugs referred to as STRIs.
  • eFFECTORs STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase interacting kinase (MNK).
  • Zotatifin, eFFECTORs inhibitor of eIF4A, is currently being evaluated in Phase 2a expansion cohorts in certain biomarker-positive solid tumors, including ER+ breast cancer and KRAS-mutant NSCLC.
  • eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E.

eFFECTOR Therapeutics Doses First Patient in Second Cohort of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19

Retrieved on: 
Wednesday, September 14, 2022
Hospital, Receptor tyrosine kinase, Plasma, EIF4E, Safety, Stri Parva, COVID-19, UCSF School of Pharmacy, University of California, San Francisco, Effector, RNA transfection, Orthornavirae, Virus, NSCLC, EIF4A, QBI, Severe acute respiratory syndrome coronavirus 2, DARPA, Review, Private Securities Litigation Reform Act, Therapy, COVID, U.S. Securities and Exchange Commission, STRI, Government, ER, Patient, Test, University of California, Cancer, Survival, Disease, Clinical trial, UCSF School of Medicine, Protein, Biology, Solution, NASDAQ, SAN, KRAS, RNA, MNK, Research, Security (finance), GLOBE, Escape Room, Pembrolizumab, University, Genome, CDK, 4F, Pfizer, Death, Pharmaceutical industry, Vaccine, Pharmacy, KICKSTART, Nature

SAN DIEGO and REDWOOD CITY, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced it has dosed the first patient in the second cohort of its Phase 1b clinical trial of zotatifin in non-hospitalized adults with confirmed COVID-19 infection. The study is a double-blind, randomized, placebo-controlled trial evaluating the safety and antiviral activity of a single dose of zotatifin and is being conducted in collaboration with the Quantitative Biosciences Institute (QBI) at the University of California, San Francisco, under a $5 million cooperative agreement sponsored by the Defense Advanced Research Projects Agency.

Key Points: 
  • Dose escalation to the second cohort comes after the positive recommendation of the independent data safety monitoring board upon review of safety data from the first dose cohort.
  • The completed cohort also included the first subjects dosed with a sub-cutaneous formulation of zotatifin and preliminary analysis demonstrated equivalent plasma drug levels compared to IV delivery.
  • Achieving equivalent drug levels when zotatifin was delivered by the sub-cutaneous route provides an opportunity for convenient dosing in both the COVID and cancer settings.
  • As such, zotatifin may have a higher barrier to viral mutational escape than therapies that target components of the virus itself.

eFFECTOR Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

Retrieved on: 
Tuesday, September 6, 2022
University, COVID-19, San Francisco, Cancer, Survival, STRI, Pfizer, Protein, Stri, DARPA, University of California, San Francisco, EIF4E, 4F, Pembrolizumab, KRAS, NSCLC, ER, Investor, Webcast, RNA transfection, MNK, EIF4A, Patient, Escape Room, Online shopping, Pharmaceutical industry, KICKSTART

A replay of the webcast will be available for 30 days following the event.

Key Points: 
  • A replay of the webcast will be available for 30 days following the event.
  • eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of oncology drugs referred to as STRIs.
  • eFFECTORs STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase interacting kinase (MNK).
  • eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E.

eFFECTOR Therapeutics Appoints Douglas Warner, M.D., as Chief Medical Officer

Retrieved on: 
Monday, August 8, 2022
U.S. Securities and Exchange Commission, Stri Parva, 4F, DARPA, Survival, UCLA Anderson School of Management, GLOBE, Duke University School of Medicine, EIF4E, University, Private Securities Litigation Reform Act, Warner, Cancer, Clinical trial, The Lancet, Security (finance), Research, Pfizer, EIF4A, STRI, NSCLC, Patient, Pembrolizumab, Therapy, CMO, COVID-19, Large-cell lung carcinoma, SAN, Effector, Amgen, NASDAQ, San Francisco, KRAS, MNK, University of California, San Francisco Fetal Treatment Center, ER, Protein, Journal, Escape Room, RNA transfection, American Journal of Clinical Oncology, Pharmaceutical industry, KICKSTART, Lancet

SAN DIEGO and REDWOOD CITY, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced it has appointed Douglas Warner, M.D., as chief medical officer.

Key Points: 
  • SAN DIEGO and REDWOOD CITY, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced it has appointed Douglas Warner, M.D., as chief medical officer.
  • He will also be responsible for developing registration strategies for both programs and exploring expansion into additional oncology indications.
  • eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of oncology drugs referred to as STRIs.
  • eFFECTOR cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements.

AUM Biosciences Announces FDA IND Authorization for Global Phase 2 Trial of Selection Translation Inhibitor AUM001 in Colorectal Cancer

Retrieved on: 
Tuesday, June 7, 2022
MSD, AUM, Phosphorylation, TME, Neoplasm, Food, RNA, Cancer, MB, Bachelor of Medicine, Bachelor of Surgery, MNK, Investigational New Drug, IND, Therapy, MSS, Pembrolizumab, FDA, GLOBE, Patient, RNA transfection, Merck Sharp & Dohme Federal Credit Union, Tumor microenvironment, CRC, Clinical trial, Cytokine, IL-6, HNRNPA1, Merck, EIF4E, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, CAP, Safety, Merck & Co., Pharmaceutical industry

As a result, AUM plans to evaluate AUM001, in combination with MSDs anti-PD-1 therapy KEYTRUDA (pembrolizumab), in a global Phase2 clinical trial in patients with microsatellite stable colorectal cancer (MSS CRC).

Key Points: 
  • As a result, AUM plans to evaluate AUM001, in combination with MSDs anti-PD-1 therapy KEYTRUDA (pembrolizumab), in a global Phase2 clinical trial in patients with microsatellite stable colorectal cancer (MSS CRC).
  • The FDAs authorization of our IND application represents a significant milestone for our lead asset AUM001, said Vishal Doshi,CEO of AUM Biosciences.
  • The planned global Phase 2 trial is an important component of our clinical development strategy, which is focused on advancing clinical trials for therapeutics candidates that are designed to reverse cancer resistance.
  • AUM Biosciences is a global clinical-stage biotech company, focused on advancing a clinical pipeline of precision oncology therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance.